TiumBio Signs Joint Clinical and Pharmaceutical Support Agreement with US MSD
[Asia Economy Reporter Lee Jung-yoon] Tium Bio announced on the 2nd that it has signed a joint clinical trial and drug support agreement with the U.S. MSD (Merck Sharp & Dohme Corp).
The joint clinical research involves conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of a combination therapy using Tium Bio's TGF-β and VEGFR2 inhibitor TU2218 and MSD's Anti PD-1 immuno-oncology drug Keytruda in patients with advanced cancer.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "The probability of a clinical trial drug ultimately receiving drug approval is statistically known to be about 10%," and added, "There is a possibility that the clinical trial and approval process may yield results that do not meet expectations, and accordingly, the company may change or abandon its commercialization plans."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
